1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. Soft Tissue and Bone Tumours. 4th ed. Geneva: WHO Press; 2020
2. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer. 2004;91:355–8. https://doi.org/10.1038/sj.bjc.6601894.
3. Knight JC, Renwick PJ, Dal Cin P, Van den Berghe H, Fletcher CD. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 1995;55:24–7.
4. Panagopoulos I, Mandahl N, Mitelman F, Aman P. Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). Oncogene. 1995;11:1133–7.
5. Trautmann M, Menzel J, Bertling C, et al. FUS-DDIT3 Fusion protein-driven IGF-IR signaling is a therapeutic target in myxoid liposarcoma. Clin Cancer Res. 2017;23:6227–38.